59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
4 citations,
October 2021 in “Canadian Journal of Physiology and Pharmacology” Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.
11 citations,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
32 citations,
January 2012 in “International Journal of Dermatology” Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
18 citations,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.